Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 388

1.

Can open-source drug R&D repower pharmaceutical innovation?

Munos B.

Clin Pharmacol Ther. 2010 May;87(5):534-6. doi: 10.1038/clpt.2010.26. Review.

PMID:
20407458
2.

Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.

Grabowski HG, Moe JL.

Cancer Prev Res (Phila). 2008 Jul;1(2):84-90. doi: 10.1158/1940-6207.CAPR-08-0048. Epub 2008 Apr 14.

3.

The future is much closer collaboration between the pharmaceutical industry and academic medical centers.

Vallance P, Williams P, Dollery C.

Clin Pharmacol Ther. 2010 May;87(5):525-7. doi: 10.1038/clpt.2010.29. Review. No abstract available.

PMID:
20407455
4.

Open innovation: public-private partnerships in pharmaceutical R&D.

Uchibayashi N.

Nihon Yakurigaku Zasshi. 2013 Jul;142(1):32-8. No abstract available.

PMID:
23842226
5.

Should financial incentives be used to differentially reward 'me-too' and innovative drugs?

Pekarsky B.

Pharmacoeconomics. 2010;28(1):1-17. doi: 10.2165/11318770-000000000-00000. Review.

PMID:
20014872
6.

Using market-exclusivity incentives to promote pharmaceutical innovation.

Kesselheim AS.

N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961. No abstract available.

7.

Open-minded to open innovation and precompetitive collaboration.

Wagner JA.

Clin Pharmacol Ther. 2010 May;87(5):511-5. doi: 10.1038/clpt.2010.39. Review. No abstract available.

PMID:
20407451
8.

How should we support pharmaceutical innovation?

Grootendorst P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):313-20. doi: 10.1586/erp.09.34.

PMID:
19670991
9.

Overcoming the obstacles in the pharma/biotech industry: 2008 update.

Graul AI, Revel L, Rosa E, Cruces E.

Drug News Perspect. 2009 Jan-Feb;22(1):39-51. doi: 10.1358/dnp.2009.22.1.1303817.

PMID:
19209298
10.

Does process excellence handcuff drug development?

Koenig J.

Drug Discov Today. 2011 May;16(9-10):377-81. doi: 10.1016/j.drudis.2011.02.010. Epub 2011 Feb 22.

PMID:
21349347
11.

Intellectual property. Balancing innovation and access: patent challenges tip the scales.

Higgins MJ, Graham SJ.

Science. 2009 Oct 16;326(5951):370-1. doi: 10.1126/science.1176116. No abstract available.

PMID:
19833944
12.

Commentary: innovation policy for a new era.

Kapczynski A.

J Law Med Ethics. 2009 Summer;37(2):264-8. doi: 10.1111/j.1748-720X.2009.00370.x.

PMID:
19493071
13.

Patents: a threat to innovation?

Manocaran M.

Science. 2010 Jan 1;327(5961):31-2; author reply 32. doi: 10.1126/science.327.5961.31. No abstract available.

PMID:
20044557
14.

Open innovation: share or die...

Talaga P.

Drug Discov Today. 2009 Nov;14(21-22):1003-5. doi: 10.1016/j.drudis.2009.09.001. Epub 2009 Sep 22. No abstract available.

PMID:
19778629
15.

Bilski blundering biotech.

Simmons WJ.

Nat Biotechnol. 2009 Mar;27(3):245-8. doi: 10.1038/nbt0309-245. No abstract available.

PMID:
19270670
16.

Trends in risks associated with new drug development: success rates for investigational drugs.

DiMasi JA, Feldman L, Seckler A, Wilson A.

Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Review.

PMID:
20130567
17.

Brazil: An emerging partner in drug R&D.

Rodrigues DG.

IDrugs. 2009 Aug;12(8):497-502. Review.

PMID:
19629884
18.

[Healthy pharmaceutical policy].

González Pier E.

Salud Publica Mex. 2008;50 Suppl 4:S488-95. Review. Spanish.

19.

Re-engineering drug discovery and development.

FitzGerald GA.

LDI Issue Brief. 2011 Oct;17(2):1-4.

PMID:
22049582
20.

Discussion point: should governments buy drug patents?

del Llano J.

Eur J Health Econ. 2007 Jun;8(2):173-7.

PMID:
17225128

Supplemental Content

Support Center